---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-077659"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:55:14.790954+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D

## Summary
- ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.
- Across all dose levels, ORR 57.7% (15/26) and DCR 88.5% (23/26) in evaluable advanced NSCLC patients.
- Safety profile: TRAEs in 27.5% (39/142), Grade≥3 SAEs in 7.7% (11/142); no TRAE-related deaths; 6 discontinuations.
- Data to be presented in mini oral at IASLC WCLC on Sept 7, 2025; builds on prior ASCO ORR of 42% (n=12).

## SEC filing metadata
- accession: 0001104659-25-077659
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/0001104659-25-077659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-077659
- JSON: https://secwatch.observer/filing/0001104659-25-077659.json
- Plain text: https://secwatch.observer/filing/0001104659-25-077659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.